Skip to main content

Table 2 Hazard ratios (HRs) and 95% confidence intervals (CIs) for the incidence of stroke, myocardial infarction, and all-cause mortality by quartile of fasting glucose variability

From: Glucose variability and the risks of stroke, myocardial infarction, and all-cause mortality in individuals with diabetes: retrospective cohort study

 

Events (n)

Follow-up duration (person-years)

Incidence rate (per 1000 person-years)

Age- and sex- Adjusted HR (95% CI)

Multivariate-adjusted HR (95% CI)

Model 1

Model 2

Stroke

 VIM Q1 (n = 156061)

6350

1185704.0

5.36

1 (Ref.)

1 (Ref.)

1 (Ref.)

 VIM Q2 (n = 156058)

6162

1191326.6

5.17

1.03 (0.99–1.07)

1.03 (0.99–1.06)

1.06 (1.02–1.09)

 VIM Q3 (n = 156060)

6214

1193013.0

5.21

1.08 (1.04–1.12)

1.05 (1.02–1.09)

1.10 (1.06–1.14)

 VIM Q4 (n = 156058)

6312

1191670.8

5.30

1.17 (1.13–1.21)

1.10 (1.07–1.14)

1.20 (1.16–1.24)

  P for trend

   

< 0.001

< 0.001

< 0.001

Myocardial infarction

 VIM Q1 (n = 156061)

3859

1194006.5

3.23

1 (Ref.)

1 (Ref.)

1 (Ref.)

 VIM Q2 (n = 156058)

3899

1199121.6

3.25

1.06 (1.01–1.11)

1.05 (1.00–1.10)

1.07 (1.02–1.12)

 VIM Q3 (n = 156060)

3978

1200620.1

3.31

1.11 (1.07–1.16)

1.09 (1.04–1.13)

1.12 (1.07–1.17)

 VIM Q4 (n = 156058)

4096

1199009.4

3.42

1.21 (1.16–1.27)

1.14 (1.09–1.20)

1.20 (1.15–1.25)

  P for trend

  

< 0.001

< 0.001

< 0.001

All-cause mortality

 VIM Q1 (n = 156061)

10506

1205853.5

8.71

1 (Ref.)

1 (Ref.)

1 (Ref.)

 VIM Q2 (n = 156058)

10608

1211059.8

8.76

1.09 (1.06–1.119)

1.08 (1.05–1.11)

1.10 (1.07–1.13)

 VIM Q3 (n = 156060)

11181

1212864.1

9.22

1.19 (1.16–1.22)

1.15 (1.12–1.18)

1.17 (1.14–1.20)

 VIM Q4 (n = 156058)

12421

1211473.9

10.25

1.40 (1.36–1.44)

1.29 (1.26–1.33)

1.32 (1.29–1.36)

  P for trend

   

< 0.001

< 0.001

< 0.001

  1. Q1:0–7.4; Q2:7.4–11.9; Q3:11.9–17.8; Q4:17.8–87.7. Model 1 is adjusted for age, sex, body mass index, alcohol drinking, smoking, regular exercise, presence of hypertension, dyslipidemia, chronic kidney disease, and lower 20% income. Model 2 is the same as model 1, plus further adjustment for duration of diabetes over 5 years, the number of classes of oral anti-diabetic medication taken in the 12 months prior to baseline, presence of prescription history of insulin, and mean of fasting glucose. VIM, variability independent of mean